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The World Health Organization (WHO) estimates that 16% of 
pregnancies are affected by gestational diabetes mellitus (GDM) 
globally.[1] Although there is a paucity of data on South African 
(SA) women, GDM prevalences of 9.1% and 25.8% have recently 
been reported.[2,3] Identifying affected women allows interventions 
to improve perinatal outcomes.[4] Both screening strategies and 
diagnostic thresholds for GDM attract controversy.[5] The 
International Association of Diabetes and Pregnancy Study Groups 
(IADPSG) advocates universal screening for GDM, but the WHO 
recommends that screening strategies be based on disease burden 
and the availability of resources.[4,6] Risk factor-based selective 
screening for GDM is currently applied in SA.[7] A selective screening 
strategy may fail to identify a high proportion of women affected by 
GDM.[8-10] In addition to being inadequate, this strategy is difficult to 
implement and women at risk may not be offered screening, even in 
well-resourced settings.[11,12]
An alternative to selective or universal application of the oral 
glucose tolerance test (OGTT) is universal screening using the 
fasting plasma glucose (FPG) level. According to the WHO 2013 
recommendation,[4] an elevated FPG of ≥5.1 mmol/L is 100% 
specific for a GDM diagnosis. However, the sensitivity of this 
diagnostic threshold varies between countries and ethnicities.[13] The 
Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study 
group has suggested that ‘in populations in which FPG is diagnostic 
in more than half of those with GDM, it may be reasonable to 
perform an accurately measured FPG as an initial step, reserving 
a full OGTT for those with a non-diagnostic FPG’.[13] The IADPSG 
acknowledges the low probability of GDM and the low risk of 
adverse outcomes in the HAPO study cohort associated with FPG 
<4.5 mmol/L.[14] Women with an FPG <4.5 mmol/L are therefore at 
low risk of GDM and may not require an OGTT. Because women 
with an FPG ≥4.5 mmol/L are at intermediate to high risk for 
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Background. Identifying women with gestational diabetes mellitus (GDM) allows interventions to improve perinatal outcomes. 
A fasting plasma glucose (FPG) level ≥5.1 mmol/L is 100% specific for a diagnosis of GDM. The International Association of Diabetes 
and Pregnancy Study Groups acknowledges that FPG <4.5 mmol/L is associated with a low probability of GDM.
Objectives. The validity of selective screening based on the presence of risk factors was compared with the universal application of FPG 
≥4.5 mmol/L to identify women with GDM. FPG ≥4.5 mmol/L or the presence of one or more risk factors was assumed to indicate an 
intermediate to high risk of GDM and therefore the need for an oral glucose tolerance test (OGTT).
Methods. Consecutive black South African (SA) women were recruited to a 2-hour 75 g OGTT at 24 - 28 weeks’ gestation in an urban 
community health clinic. Of 969 women recruited, 666 underwent an OGTT, and of these 589 were eligible for analysis. The glucose 
oxidase laboratory method was used to measure plasma glucose concentrations. The World Health Organization GDM diagnostic 
criteria were applied. All participants underwent a risk factor assessment. The χ2 test was used to determine associations between 
risk factors and a positive diagnosis of GDM. The sensitivity and specificity of a positive diagnosis of GDM were calculated for FPG 
≥4.5 mmol/L, FPG ≥5.1 mmol/L, and the presence of one or more risk factors.
Results. The prevalence of overt diabetes mellitus and GDM was 0.5% and 7.0%, respectively. Risk factor-based selective screening 
indicated that 204/589 (34.6%) of participants needed an OGTT, but 18/41 (43.9%) of positive GDM diagnoses were missed. Universal 
screening using the FPG threshold of ≥4.5 mmol/L indicated that 152/589 (25.8%) of participants needed an OGTT, and 1/41 (2.4%) 
of positive diagnoses were missed. An FPG of ≥5.1 mmol/L identified 36/41 (87.8%) of GDM-positive participants. The sensitivity and 
specificity of the presence of one or more risk factors were 56% and 67%, respectively. The sensitivity and specificity of FPG ≥4.5 mmol/L 
were 98% and 80%, respectively.
Conclusions. Universal screening using FPG ≥4.5 mmol/L had greater sensitivity and specificity in identifying GDM-affected women 
and required fewer women to undergo a resource-intensive diagnostic OGTT than risk factor-based selective screening. A universal 
screening strategy using FPG ≥4.5 mmol/L may be more efficient and cost-effective than risk factor-based selective screening for GDM 
in black SA women.
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GDM, they would require an OGTT. This FPG threshold has been 
suggested for use in low-resource settings, as it reduces the number 
of women requiring an OGTT. Use of this threshold would also avoid 
missed diagnoses in populations where the sensitivity of the FPG may 
be suboptimal or unknown.[14-16]
Objectives
To compare the utility of this universally applied dual FPG threshold, 
namely that ≥4.5 mmol/L indicates that formal screening is required 
and <4.5 mmol/L rules out GDM. The sensitivity and specificity 
were compared with the current standard practice of risk factor-
based selective screening in identifying urban black African women 
affected by GDM.
Methods
Ethical considerations
The University of the Witwatersrand Human Research Ethics 
committee reviewed and approved the study protocols (ref. no. 
M150365). The Johannesburg District Department of Health granted 
permission to conduct this study in Soweto, Johannesburg (ref. no. 
2015–16/031). All participants gave written informed consent.
Design
This cross-sectional, pragmatic, prospective study took place at a 
single urban community health clinic (CHC) between April 2016 and 
May 2017. Consecutive women were recruited at their first antenatal 
clinic visit. Women at <28 weeks’ gestation were eligible for inclusion, 
and we excluded those aged <18 years and those known to have 
type 1 or type 2 diabetes mellitus. Gestational age was determined 
by the clinic nurse as part of usual care. There were no ultrasound 
facilities on site. Study procedures were conducted within the usual 
functioning of the antenatal service of the CHC.
Participants
Data gathered from all participants included risk factors for GDM 
as defined by the SA National Department of Health (NDoH).[7] 
These include maternal obesity (body mass index (BMI) ≥35 kg/m2, 
which is WHO obesity class ≥II), maternal age ≥40 years, previous 
history of GDM, first-degree relative with diabetes mellitus, previous 
unexplained intrauterine fetal death, previous macrosomic baby, or 
complications in the current pregnancy including polyhydramnios, 
fetus large for gestational age or the presence of repeated glycosuria. [5] 
All participants in the study were of black African ethnicity, in 
keeping with this clinic’s patient profile, so the NDoH risk factor of 
being of South Asian descent did not apply. Additional data collected 
included gestation at the first antenatal visit, parity, cigarette smoking, 
history of chronic hypertension, and blood pressure and mid-upper 
arm circumference measurements.[17,18] Participants were frequently 
unable to recall exact birth weights of their previous babies, so the 
terms ‘small’, ‘average or ‘large’ were used instead, as was standard 
practice at this clinic.
Oral glucose tolerance test
All participants underwent a 2-hour 75 g glucose OGTT in the 
morning after an overnight fast at 24 - 28 weeks’ gestation. Venous 
blood samples were collected in tubes containing the glycolytic 
inhibitor sodium fluoride (BD 454297), and samples were kept 
on ice ex vivo. The use of sodium fluoride tubes is included in the 
WHO-recommended OGTT procedure.[19] Typically, there are no 
on-site laboratories at CHCs in SA. All venous blood samples were 
delivered to the off-site laboratory, which was 14 km away, within an 
hour of completion of the OGTTs. This research laboratory used 
the glucose oxidase method (RX daytona+; Randox Laboratories, 
USA) to determine plasma glucose concentrations. On request, 
the laboratory provided us with its quality control results. At 
mean glucose concentrations of 6.36 mmol/L and 15.80 mmol/L, 
the analytical coefficients of variation (CVs) were 1.85% and 
1.67%, with a bias of 0.35% and 0.31%, respectively. These quality 
control results are within the recommendation of the American 
National Academy of Clinical Biochemistry (NACB) for laboratory 
measurements of plasma glucose (a CV of ≤2.9% and a bias of 
≤2.2%).[20] Trained research staff operated independently from the 
CHC staff.
Clinical diagnostic criteria
The WHO 2013 diagnostic criteria,[4] which were endorsed by the 
Society of Endocrinology, Metabolism, and Diabetes of South Africa 
(SEMDSA) in 2017,[21] were used to define OGTT cut-offs for a 
positive GDM diagnosis. Only one plasma glucose abnormality in the 
2-hour OGTT is necessary for a positive diagnosis of GDM. GDM 
is defined as a plasma glucose concentration of 5.1  - 6.9 mmol/L at 
fasting, ≥10.0 mmol/L at 1 hour of the OGTT or 8.5 - 10.9 mmol/L at 
2 hours. Diagnostic thresholds for overt diabetes in pregnancy, which 
indicates probable preconception diabetes, are a plasma glucose 
concentration ≥7.0 mmol/L at fasting or ≥11.0 mmol/L at 2 hours of 
the OGTT. Participants diagnosed with overt diabetes or GDM were 
referred for clinical intervention.
Sample size
This analysis was part of a research study to assess the feasibility of 
implementing a universal screening, diagnosis and GDM lifestyle 
intervention programme in a low-resource urban setting.[22,23] We 
intended to identify 100 GDM-positive women for the purpose 
of participating in the GDM lifestyle intervention. Based on an 
estimated 16% global prevalence, 625 consecutive participants would 
need to be recruited.
Statistical analysis
Categorical variables were described as frequencies and proportions 
(%) and continuous variables as means and standard deviations 
(SDs). The χ2 test was used to determine associations between 
categorical variables, especially between known risk factors and a 
positive GDM diagnosis. Fisher’s exact test was used in cases where 
expected frequencies were <5. In this analysis, FPG thresholds were 
retrospectively used to indicate the need for an OGTT, and the 
categories were low risk (<4.5 mmol/L), meaning no need for an 
OGTT, and intermediate to high risk (≥4.5 mmol/L), indicating the 
need for a formal diagnostic OGTT to determine the presence and 
extent of dysglycaemia. The sensitivity, specificity, positive predictive 
values (PPVs), negative predictive values (NPVs), positive likelihood 
ratios (PLRs) and negative likelihood ratios (NLRs) for a positive 
GDM diagnosis were calculated for FPG ≥4.5 mmol/L and FPG 
≥5.1  mmol/L as well as for the presence of one or more NDoH-
defined risk factors for GDM. We also evaluated the utility of a 
modified NDoH-recommended risk score using BMI ≥30  kg/m2 
(obesity class I) rather than the standard BMI ≥35 kg/m2 (obesity 
class ≥II). [21] A p-value <0.05 was assumed to be statistically 
significant, and 95% confidence intervals (CIs) are presented where 
appropriate. Statistical analyses were performed on STATA software 
version 15 (StataCorp LLC, USA). SAS version 9.4 software (SAS 
Institute Inc., USA) macro NLEstimate was used to compute model-
based 95% CIs for the likelihood ratios.
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Results
Participants
Of the 1 270 women who attended the antenatal clinic over the 
12-month recruitment period of the study, 969 (76.3%) were willing 
and eligible to participate. Of the 666 participants who had an 
OGTT, 589 had a complete data set that was submitted for analysis. 
The number of women recruited and the reasons for the attrition 
of participant numbers before data analysis are presented in Fig. 1. 
Overt diabetes mellitus was identified in 3/589 participants (0.5%), 
and GDM was present in 41/589 (7.0%) (95% CI 4.9 - 9.2). The mean 
(SD) BMI of 26.9 (5.8) kg/m2 indicates that, overall, participants in 
the study were overweight; 57/589 participants (9.7%) had a BMI 
≥35 kg/m2 and 16/589 (2.7%) had a BMI ≥40 kg/m2. Six participants 
were glycosuria-positive on one occasion  with no opportunity for 
repeat glycosuria testing prior to the elective OGTT. Participant 
characteristics are presented in Table 1.
Characteristics of GDM-positive women
GDM-positive women were significantly more overweight than their 
non-GDM counterparts, with 6.1 kg (p=0.017; 95% CI 1.1 - 11.1) 
heavier body weight and a mid-upper arm circumference that was 
2.1  cm (p=0.004; 95% CI 0.7 - 3.4) greater; they were also older 
(p<0.001), presented later in pregnancy for their first antenatal visit 
(p=0.001) and had higher diastolic blood pressure (p=0.004). Of 
the 41 GDM-positive participants, 5 (12.2%) were pregnant for the 
first time and 27 (63.4%) were pregnant for the third time or more. 
This higher parity was associated with an increased risk of GDM 
(p<0.001). Unexpectedly, in this study population, a positive family 
history of diabetes mellitus was not associated with a positive GDM 
diagnosis (p=0.591) (Table 1).
Assessment of risk factors
Based on the current NDoH guidelines (which include BMI ≥35 kg/ 
m2), 204/589 (34.6%) of the participants had one or more risk factors 
for GDM and would have required an elective OGTT; however, 18/41 
GDM-positive cases (43.9%) would have been missed. At a BMI 
≥30  kg/m2, the number of participants requiring an OGTT would 
have been 262/589 (44.5%) and the number of missed GDM-positive 
cases would have been reduced to 12/41 (29.3%) (Table 2). A selective 
screening strategy based on the presence of two or more NDoH risk 
factors (including BMI ≥35 kg/m2) had a sensitivity, specificity, PPV, 
NPV, PLR and NLR of 23% (95% CI 11 - 38), 88% (95% CI 86 - 91), 
13% (95% CI 6 - 22), 94% (95% CI 92 - 96), 1.95 (95% CI 1.05 - 3.63) 
and 0.88 (0.74 - 1.04), respectively. The use of two or more risk factors 
(including BMI ≥35 kg/m2) would have resulted in 33/41 (80.5%) of 
GDM-positive cases being missed.
Assessment of laboratory results
The mean  plasma glucose concentrations  at fasting and 60 and 
120 minutes of the OGTT were 4.01 mmol/L (95% CI 3.95 - 4.07), 
5.42 mmol/L (95% CI 5.30 - 5.54) and 5.12 mmol/L (95% CI 5.01 - 
5.23), respectively. The number of abnormalities per time point of 
the OGTT is presented in a Venn diagram (Fig. 2). The use of FPG 
≥5.1 mmol/L as a universal screening strategy for GDM would 
have required 36 (6.1%) of 589 participants to undergo an OGTT; 
however, 5 (12.2%) of the 41 GDM-positive participants would have 
been missed. Based on the dual-threshold screening strategy, if those 
participants with an FPG <4.5 mmol/L were assumed to be at low risk 
and so were not formally screened, 152 (25.8%) of 589 participants 
would have required an OGTT and 40 (97.6%) of the 41 with GDM 
would have been identified (Table 2).
Discussion
The prevalence of GDM as determined by the glucose oxidase 
laboratory method in this routine clinical setting in a population 
of urban black African women attending a single CHC was 7.0%. 
Our results have similarities to and differences from recent SA 
reports of GDM prevalence. Macauley et al.[3] reported a 9.1% 
GDM prevalence in a tertiary hospital setting, using a research 
laboratory (glucose oxidase method), and their participants had a 
higher risk profile for GDM than participants at the CHC where this 
study was conducted. [3] A study by Adam and Rheeder[24] possibly 
overestimated the GDM prevalence at 25.8%, and one reason for this 
is that the laboratory bias of 3.65%, which is not within the ≤2.2% 
recommended by the NACB,[20] would adversely affect the quality of 
plasma glucose measures.
Importantly, 87.8% of GDM-positive diagnoses in this study 
population were based on an elevated FPG. This confirms the 
Women approached for screening 
at primary healthcare clinic, N=1 270
Not eligible, n=301
• Age <18 years
• >28 weeks' gestation
• Known type 1 or 2 DM
Eligible participants recruited, n=969
Did not complete the OGTT, n=303
• Lost contact, n=58
• Relocated residence, n=31
• School/work/unavailable, n=36
• Sick/hospitalised on test day, n=5
• Failed to keep appointment, n=95
• Pregnancy loss or preterm birth, n=62
• Tested at tertiary hospital, n=7
• Consent withdrawn, n=9
Participants screened for GDM, n=666
OGTT incomplete, n=14
• No venous access, n=11
• Participant vomited glucose solution, n=3
Data incomplete, n=63
Data for analysis, n=589
Fig. 1. Consort diagram of participant recruitment. (OGTT = oral glucose 
tolerance test; GDM = gestational diabetes mellitus.)
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findings of Macauley et al.[3] and Adam and Rheeder[24] that the 
majority of GDM diagnoses in SA women screened were based 
on an elevated FPG. The use of FPG alone to screen for GDM is 
attractive as it is less expensive than a complete OGTT, avoids the 
need for multiple punctures, reduces laboratory workload, and avoids 
exposing pregnant women to the sometimes emesis-inducing oral 
glucose load.[25,26] There is outcomes-based evidence that an elevated 
FPG alone is comparable to a complete OGTT in predicting large-
for-gestational-age infants, and for indicating the need for insulin 
treatment of GDM.[27-29] Although an FPG ≥5.1 mmol/L is 100% 
specific for a diagnosis of GDM, the sensitivity of this diagnostic 
threshold varies between countries and ethnicities in both low- 
and high-risk populations.[13,16,30,31] When retrospectively applied 
to the HAPO study cohort, the mean proportion of GDM-positive 
diagnoses based on an elevated FPG was 55% (range 24 - 74%), and 
this figure varied between and within countries.[13] The underlying 
mechanism responsible for this variability is unknown. Sub-Saharan 
Africa was not included in the HAPO study. The prevalence of 
Table 1. Participant characteristics, with comparison of GDM-positive and GDM-negative women*
Clinical characteristics
All participants (N=589) GDM-positive (N=41) GDM-negative (N=548)
p-valueN Variable N Variable N Variable
Age (years), mean (SD) 589 27.8 (5.9) 41 31.1 (6.9) 548 27.5 (5.7) <0.001†
History of chronic hypertension, n (%) 588 19 (3.2) 41 1 (2.5) 547 18 (3.3) 1.000‡
Active smoker (cigarettes), n (%) 589 21 (3.6) 41 4 (10.0) 548 17 (3.1) 0.051‡
Family history of diabetes, n (%) 585 99 (16.9) 40 8 (20.0) 545 91 (16.6) 0.591§
Glycosuria (urine dipstick), n (%) 589 6 (1.0) 41 2 (4.9) 548 4 (0.7) -
MUAC (cm), mean (SD) 589 29.9 (4.4) 41 31.8 (4.3) 548 29.7 (4.4) 0.004†
Body height (cm), mean (SD) 588 162.1 (6.6) 40 160.7 (6.2) 548 162.2 (6.6) 0.152†
Body weight (kg), mean (SD) 589 70.7 (15.7) 41 76.4 (15.3) 548 70.3 (15.7) 0.017†
BMI (kg/m²), mean (SD) 588 26.9 (5.8) 40 29.2 (5.3) 548 26.7 (5.8) 0.009†
Systolic BP (mmHg), mean (SD) 588 122.3 (14.9) 41 122.8 (19.9) 547 122.2 (14.5) 0.200¶
Diastolic BP (mmHg) 588 72.6 (11.0) 41 77.4 (9.6) 547 72.2 (11.0) 0.004†
GA at first visit (weeks), mean (SD) 589 19.1 (5.6) 41 22.0 (4.2) 548 18.9 (5.6) <0.001†
Number of pregnancies including current, n (%)
≥2 589 417 (70.8) 41 35 (85.4 ) 548 382 (69.7) 0,033§
≥3 589 223 (37.9) 41 27 (65.9) 548 196 (35.8) <0.001§
>3 589 79 (13.4) 41 9 (22.0) 548 70 (12.8) 0,096§
Previous LGA birth, n (%) 588 43 (7.3) 41 6 (14.6) 547 37 (6.8) 0.108‡
Previous stillbirth, n (%) 589 32 (5.4) 41 3 (7.5) 548 29 (5.3) 0.481‡
Previous congenital abnormalities, n 588 0 41 0 548 0 -
Previous GDM, n (%) 589 3 (0.5) 41 1 (2.4) 548 2 (0.4) -
GDM = gestational diabetes mellitus; SD = standard deviation; MUAC = mid-upper arm circumference; BMI = body mass index; BP = blood pressure; LGA = large for gestational age.
*Numbers of participants for each characteristic vary slightly owing to missing values.
†Student’s t-test. 
‡Fisher’s exact text.
§χ2 test.
¶Mann-Whitney U-test.
Table 2. Validity measures of GDM screening: universal strategy with FPG ≥5.1 mmol/L, universal strategy with FPG ≥4.5 mmol/L, selective 
risk factor-based strategy including a BMI ≥30 kg/m2, and selective risk factor-based strategy including a BMI ≥35 kg/m2
Universal screening based on dual-
threshold FPG v. universal OGTT
Selective screening strategy based  
on risk factors v. universal OGTT
FPG ≥5.1 mmol/L FPG ≥4.5 mmol/L 
≥1 risk factor(s) 
including BMI ≥30 kg/m2 
≥1 risk factor(s)  
including BMI ≥35 kg/m2 
Participants, N 589 589 589 589
True positive, n 36 40 29 23
False positive, n 0 112 233 181
True negative, n 548 436 315 367
False negative, n 5 1 12 18
Sensitivity, % (95% CI) 88 (74 - 96) 98 (87 - 100) 71 (54 - 84) 56 (40 - 72)
Specificity, % (95% CI) 100 80 (76 - 83) 57 (53 - 61) 67 (63 - 71)
PPV, % (95% CI) 100 26 (20 - 34) 11 (8 - 16) 11 (7 - 16)
NPV, % (95% CI) 99 (98 - 100) 99 (99 - 100) 96 (94 - 98) 95 (93 - 97)
PLR (95% CI) Undefined 4.77 (3.95 - 5.60) 1.66 (1.30 - 2.03) 1.70 (1.19 - 2.20)
NLR (95% CI) 0.12* 0.03 (–0.03 - 0.09) 0.51 (0.26 - 0.75) 0.66 (0.43 - 0.89)
GDM = gestational diabetes mellitus; FPG = fasting plasma glucose; OGTT = oral glucose tolerance test; PPV = positive predictive value; NPV = negative predictive value;  
PLR = positive likelihood ratio; NLR = negative likelihood ratio.
*Model did not converge to yield 95% CIs.
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elevated FPG in multiethnic SA, affected by historical undernutrition 
and a current high burden of obesity, is unknown, and the use of 
a single value of the OGTT may miss GDM-affected women. The 
low-cost algorithm of a dual-threshold FPG, with ≥5.1 mmol/L 
(specificity 100%) used to rule in GDM and <4.5 mmol/L to rule 
it out, was associated with a reduction in the need for a complete 
OGTT when applied to the HAPO, United Arab Emirates and 
Brazilian cohorts.[13,15,16] In order to improve accessibility to screening, 
it may be possible to screen women for GDM with point-of-care 
testing, thus reducing the need for more expensive and sometimes 
inaccessible laboratory services. The use of glucometers to screen 
for and diagnose DM and GDM is endorsed by the WHO[1] and 
the International Federation of Gynecology and Obstetrics.[32] The 
reliable use of selected plasma calibrated glucometers to measure 
FPG in a universal GDM screening programme in a low-resource SA 
setting was recently reported.[22]
Maternal obesity was strongly associated with a positive GDM 
diagnosis in this study. SA has a high prevalence of obesity, 
which is associated with an increased risk of insulin resistance 
and dysglycaemia.[33,34] Epidemiologically, the prevalence of GDM 
increases by 0.9% per one point increase in BMI.[35] In this study, the 
use of BMI ≥30 kg/m2 was associated with an increased sensitivity 
compared with a BMI ≥35 kg/m2.[36] Based on the current screening 
strategy of risk factor-based selective screening, a high proportion of 
SA women may require an OGTT, posing a potentially overwhelming 
burden to existing healthcare and laboratory services. The low 
sensitivity and specificity of a risk factor assessment to identify SA 
women with GDM in this study confirms the findings of Adam and 
Rheeder.[2] The low reliability of risk factor-based selective screening 
in SA women is aligned with international findings that almost half 
of GDM-affected women will be missed by selective screening based 
on conventional risk factors.[6,32] In 2017, SEMDSA adopted the 
WHO 2013 diagnostic thresholds for GDM, with a suggestion that 
a universal screening strategy could be implemented only in well-
resourced settings in SA.[21] A previous report suggests that rural-
dwelling SA women may be at high risk of diabetes in pregnancy. [38] 
Ideally, equal access to GDM screening should be available to all 
pregnant women, whether in a private or state healthcare setting, 
whether urban or rural dwelling, and regardless of ethnicity.
Prior to the WHO revision of GDM diagnostic thresholds in 2013, 
there was evidence that plasma glucose concentration abnormalities 
at all time points of the OGTT could predict the need for insulin 
therapy.[39] There are no prediction models for which GDM-affected 
women are likely to need oral hypoglycaemic agents or insulin 
treatment to restore euglycaemia during pregnancy. In addition, 
increases in fasting and 2-hour plasma glucose concentrations are 
associated with an increased risk of developing overt diabetes in later 
years.[40] For this reason, in the event that a GDM diagnosis is made 
based on an elevated FPG, it may be necessary to perform a complete 
OGTT.
Study strengths and limitations
This translational research project was conducted within the usual 
functioning of a CHC, which equates to routine care rather than a 
research clinical setting. Our participants were urban black African 
women attending the antenatal service of a single urban CHC, so 
our results may not be generalisable beyond this population profile. 
The sample size and the low GDM prevalence of 7.0% (95% CI 4.9 - 
9.2) were insufficient to provide robust estimates of the sensitivity 
of the FPG screening threshold of ≥4.5 mmol/L. Further studies in 
more diverse patient populations and clinical settings are needed to 
confirm these results.
Conclusions
A universally applied FPG threshold of ≥4.5 mmol/L, as an indicator 
of intermediate to high risk of GDM improved sensitivity and 
reduced the number of women needing to undergo the unpleasant, 
poorly reproducible and resource-intensive OGTT compared with 
the current practice of risk factor-based selective screening.
Research highlights
Overt diabetes and gestational diabetes prevalences were 0.5% and 
7.0%, respectively.
• Selective risk factor screening indicated that 34.6% of women 
needed an OGTT, but missed 43.9% of GDM.
• Universally applied FPG ≥5.1 mmol/L identified 87.8% of GDM-
positive women.
• Universally applied FPG ≥4.5 mmol/L indicated that 25.8% of 
women needed an OGTT but missed 2.4% of GDM.
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